补气活血中药在新型冠状病毒肺炎低氧血症的潜在临床应用价值及其机制浅析  

Exploration of potential clinical application value and mechanism of Chinese materia medica for tonifying qi and activating blood in COVID-19 with hypoxemia

作　　者：张依倩[1,2] 史嘉雯 刘园华 周浩 蔡晓庆[4] 温晋 刘元雪 任红微 王玉 宋兆辉[1,2,6] 何毅 孙鹤[1,2] 周水平[1,2] 陈韵岱 ZHANG Yi-qian;SHI Jia-wen;LIU Yuan-hua;ZHOU Hao;CAI Xiao-qing;WEN Jin;LIU Yuan-xue;REN Hong-wei;WANG Yu;SONG Zhao-hui;HE Yi;SUN He;ZHOU Shui-ping;CHEN Yun-dai(TCM Research Center,Tasly Academy,Tasly Holding Group Co.,Ltd.,Tianjin 300410,China;State Key Laboratory of Critical Technology in Innovative Chinese Medicine,Tasly Pharmaceutical Group Co.,Ltd.,Tianjin 300410,China;Department of Cardiology,the First Medical Center of Chinese PLA General Hospital,Beijing 100853,China;940 Hospital,Joint Logistic Support Force of PLA,Lanzhou 730050,China;School of Pharmaceutical Science and Technology,Tianjin University,Tianjin 300072,China;Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China)

机构地区：[1]天士力控股集团有限公司研究院现代中药开发中心,天津300410 [2]天士力医药集团股份有限公司创新中药关键技术国家重点实验室,天津300410 [3]解放军总医院第一医学中心心内科,北京100853 [4]解放军联勤保障部队第940医院,甘肃兰州730050 [5]天津大学药物科学与技术学院,天津300072 [6]天津中医药大学,天津30161

出　　处：《中草药》2020年第6期1435-1442,共8页Chinese Traditional and Herbal Drugs

基　　金：国家“重大新药创制”科技重大专项(2017ZX09301005)。

摘　　要：针对新型冠状病毒(SARS-CoV-2)所致的肺炎(COVID-19)疫情,国家卫生健康委员会、国家中医药管理局在2020年1月22日发布的《新型冠状病毒感染的肺炎诊疗方案(试行第三版)》中首次提出了中医治疗的方案,并逐步更新至第七版。确诊的COVID-19重症患者多在发病一周后出现呼吸困难和/或低氧血症,需要给予呼吸支持和循环支持,通过文献调研发现补气活血中药可有效改善肺炎相关疾病低氧血症,因此总结归纳了现有补气活血中药治疗肺炎相关疾病低氧血症的临床应用和作用机制研究进展,为COVID-19的临床用药提供参考。For SARS-CoV-2-induced pneumonia, "Diagnosis and Treatment of Novel Coronavirus Pneumonia(trial version 3)" released by the National Health Commission of the People’s Republic of China and the National Administration of Traditional Chinese Medicine on January 22, 2020, first proposed the traditional Chinese medicine(TCM) treatment plan, which was gradually updated to the seventh edition. Patients diagnosed with severe COVID-19 often developed dyspnea and/or hypoxemia one week after onset, requiring respiratory support and circulation support. Through literature research, it was found that Chinese materia medica(CMM) with tonifying qi and activating blood effect could effectively improve hypoxemia of pneumonia-related diseases. This article summarizes the mechanism and clinical application of tonifying qi and activating blood CMM in the treatment of novel coronavirus pneumonia-associated hypoxemia, and provides a reference for clinical treatment of COVID-19.

关 键 词：新型冠状病毒肺炎 补气活血 低氧血症 氧饱和度 氧合指数 

分 类 号：R285[医药卫生—中药学]